Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels
Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels
复制标题
DOI：
10.1182/blood-2014-07-584953
复制
发表时间：
2014-11-06
期刊：
影响因子：
20.3
通讯作者：
de Leval, Laurence
中科院分区：
文献类型：
--
作者：
Bossard, Celine;Dobay, Maria Pamela;de Leval, Laurence
据报告，维布妥昔单抗-维多汀在CD 30（+）非间变性外周T细胞淋巴瘤（PTCL）中的扩展使用具有良好的疗效。因此，CD 30状态评估是治疗决策的关键因素，但免疫组化（IHC）在评估其表达的可靠性仍有待确定。这促使我们在376例代表主要实体的非皮肤PTCL的队列中研究通过IHC进行的半定量CD 30蛋白评估与通过微阵列进行的信使RNA（mRNA）评估之间的相关性。通过IHC，CD 30表达在实体之间和实体内是异质的，并且与大的肿瘤细胞大小显著相关。除了100%的间变性大细胞淋巴瘤外，57%的其他PTCL实体在5%的阈值下为CD 30阳性。CD 30蛋白表达与mRNA水平高度相关。mRNA水平呈双峰型，区分高表达和低表达CD 30的PTCL病例。我们的结论是，免疫组化是一个有价值的工具，在临床实践中，以评估CD 30的表达PTCL。
The extended use of brentuximab-vedotin was reported for CD30(+) nonanaplastic peripheral T-cell lymphomas (PTCLs) with promising efficacy. CD30 status assessment is thus a critical factor for therapeutic decision, but the reliability of immunohistochemistry (IHC) in evaluating its expression remains to be defined. This prompted us to investigate the correlation between semiquantitative CD30 protein assessment by IHC and messenger RNA(mRNA) assessment by microarrays in a cohort of 376 noncutaneous PTCLs representative of the main entities. By IHC, CD30 expression was heterogeneous across and within entities and significantly associated with large tumor cell size. In addition to 100% anaplastic large-cell lymphomas, 57% of other PTCL entities were CD30-positive at a 5% threshold. CD30 protein expression was highly correlated to mRNA levels. mRNA levels were bimodal, separating high from low CD30-expressing PTCL cases. We conclude that IHC is a valuable tool in clinical practice to assess CD30 expression in PTCLs.